View in EDS HTML Full Text PDF Full Text

Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia.

Saved in:
Bibliographic Details
Title: Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia.
Authors: Settumba, Stella (AUTHOR), Shahbazi, Jeyran (AUTHOR), Byrne, Marianne (AUTHOR), Degenhardt, Louisa (AUTHOR), Grebely, Jason (AUTHOR), Larance, Briony (AUTHOR), Nielsen, Suzanne (AUTHOR), Lintzeris, Nicholas (AUTHOR), Ali, Robert (AUTHOR), Rodgers, Craig (AUTHOR), Blazey, Alison (AUTHOR), Weiss, Robert (AUTHOR), Dunlop, Adrian (AUTHOR), McDonough, Michael (AUTHOR), Cook, Jon (AUTHOR), Farrell, Michael (AUTHOR)
Source: Drug & Alcohol Review. Jan2025, Vol. 44 Issue 1, p179-194. 16p.
Subjects: Buprenorphine, Cost analysis, Opioid abuse, Cost benefit analysis, Medical care, Medical care costs
Geographic Terms: Australia
Abstract: Introduction: The costs of providing medication‐assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended‐release buprenorphine (BUP‐XR), we performed a bottom‐up costing analysis of provider operational treatment costs. Methods: Data were collected in a single‐arm open label trial of BUP‐XR injections conducted in specialist public drug treatment services and primary care private practices in three Australian states (the CoLAB study). The unit costs of resources used for each activity were combined with quantities used at each participating facility to arrive at the average annual cost per client. Results: One hundred participants across the six health facility sites received monthly subcutaneous BUP‐XR injections administered by a health‐care practitioner. The average cost of providing 1 year of treatment per participant was $6656 ($6026–$8326). Screening cost (initial assessment and medical history) was $282 while monthly follow‐up appointments cost $531 per client. The main cost driver was the monthly treatment costs accounting for 79% of the average annual client cost, with medication costs comprising 95% of this cost. Discussion and Conclusion: With medication costs making up the largest proportion of treatment costs, treatment using BUP‐XR has the potential to free up other health system resources, for example, staff time. The costs reported in this study can be used in an economic evaluation to estimate the net benefit or cost‐effectiveness of BUP‐XR especially when compared to other opioid agonist treatments. [ABSTRACT FROM AUTHOR]
Copyright of Drug & Alcohol Review is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 183913576
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Settumba%2C+Stella%22">Settumba, Stella</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shahbazi%2C+Jeyran%22">Shahbazi, Jeyran</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Byrne%2C+Marianne%22">Byrne, Marianne</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Degenhardt%2C+Louisa%22">Degenhardt, Louisa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grebely%2C+Jason%22">Grebely, Jason</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Larance%2C+Briony%22">Larance, Briony</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nielsen%2C+Suzanne%22">Nielsen, Suzanne</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lintzeris%2C+Nicholas%22">Lintzeris, Nicholas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ali%2C+Robert%22">Ali, Robert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rodgers%2C+Craig%22">Rodgers, Craig</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Blazey%2C+Alison%22">Blazey, Alison</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weiss%2C+Robert%22">Weiss, Robert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dunlop%2C+Adrian%22">Dunlop, Adrian</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22McDonough%2C+Michael%22">McDonough, Michael</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cook%2C+Jon%22">Cook, Jon</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Farrell%2C+Michael%22">Farrell, Michael</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Drug+%26+Alcohol+Review%22">Drug & Alcohol Review</searchLink>. Jan2025, Vol. 44 Issue 1, p179-194. 16p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Buprenorphine%22">Buprenorphine</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+analysis%22">Cost analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Opioid+abuse%22">Opioid abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+benefit+analysis%22">Cost benefit analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care%22">Medical care</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care+costs%22">Medical care costs</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Australia%22">Australia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: The costs of providing medication‐assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended‐release buprenorphine (BUP‐XR), we performed a bottom‐up costing analysis of provider operational treatment costs. Methods: Data were collected in a single‐arm open label trial of BUP‐XR injections conducted in specialist public drug treatment services and primary care private practices in three Australian states (the CoLAB study). The unit costs of resources used for each activity were combined with quantities used at each participating facility to arrive at the average annual cost per client. Results: One hundred participants across the six health facility sites received monthly subcutaneous BUP‐XR injections administered by a health‐care practitioner. The average cost of providing 1 year of treatment per participant was $6656 ($6026–$8326). Screening cost (initial assessment and medical history) was $282 while monthly follow‐up appointments cost $531 per client. The main cost driver was the monthly treatment costs accounting for 79% of the average annual client cost, with medication costs comprising 95% of this cost. Discussion and Conclusion: With medication costs making up the largest proportion of treatment costs, treatment using BUP‐XR has the potential to free up other health system resources, for example, staff time. The costs reported in this study can be used in an economic evaluation to estimate the net benefit or cost‐effectiveness of BUP‐XR especially when compared to other opioid agonist treatments. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Drug & Alcohol Review is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=183913576
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dar.13956
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 179
    Subjects:
      – SubjectFull: Buprenorphine
        Type: general
      – SubjectFull: Cost analysis
        Type: general
      – SubjectFull: Opioid abuse
        Type: general
      – SubjectFull: Cost benefit analysis
        Type: general
      – SubjectFull: Medical care
        Type: general
      – SubjectFull: Medical care costs
        Type: general
      – SubjectFull: Australia
        Type: general
    Titles:
      – TitleFull: Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Settumba, Stella
      – PersonEntity:
          Name:
            NameFull: Shahbazi, Jeyran
      – PersonEntity:
          Name:
            NameFull: Byrne, Marianne
      – PersonEntity:
          Name:
            NameFull: Degenhardt, Louisa
      – PersonEntity:
          Name:
            NameFull: Grebely, Jason
      – PersonEntity:
          Name:
            NameFull: Larance, Briony
      – PersonEntity:
          Name:
            NameFull: Nielsen, Suzanne
      – PersonEntity:
          Name:
            NameFull: Lintzeris, Nicholas
      – PersonEntity:
          Name:
            NameFull: Ali, Robert
      – PersonEntity:
          Name:
            NameFull: Rodgers, Craig
      – PersonEntity:
          Name:
            NameFull: Blazey, Alison
      – PersonEntity:
          Name:
            NameFull: Weiss, Robert
      – PersonEntity:
          Name:
            NameFull: Dunlop, Adrian
      – PersonEntity:
          Name:
            NameFull: McDonough, Michael
      – PersonEntity:
          Name:
            NameFull: Cook, Jon
      – PersonEntity:
          Name:
            NameFull: Farrell, Michael
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09595236
          Numbering:
            – Type: volume
              Value: 44
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Drug & Alcohol Review
              Type: main
ResultId 1